Results 261 to 270 of about 119,295 (311)
Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. [PDF]
Colorectal DisAppleyard JW +10 more
europepmc +1 more source
The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies. [PDF]
Int J Mol SciKwiatkowska L, Szczuko M.
europepmc +1 more source
Odontogenic Keratocysts Don't Harbor BRAF Mutation: A Genetic and Immunohistochemical Analysis
Oral Diseases, EarlyView.
Raisa Severino‐Lazo +6 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
BRAF Heterogeneity in Melanoma
Current Treatment Options in Oncology, 2021In the era of molecular targeted therapy, the accurate detection of BRAF mutation in melanoma has become increasingly important. With the advances of molecular analyses and immunohistochemistry, the presence of BRAF mutational heterogeneity in melanoma has been widely recognized.
Takamichi Ito +5 more
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2020
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between ...
Frisone D. +4 more
openaire +4 more sources
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between ...
Frisone D. +4 more
openaire +4 more sources
Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
The Lancet Oncology, 2016Refers to Planchard D, Besse B, Groen HJM, Souquet P, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial ...
Gareth, Rivalland, Paul, Mitchell
openaire +2 more sources
Radiosensitization by BRAF inhibitors
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017BackgroundIncreased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported.Material and MethodsWe present seven melanoma patients with non‐resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy.ResultsIn all patients, combination therapy yielded a
Strobel, Sophia Boyoung +5 more
openaire +3 more sources
BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.
Journal of Clinical Oncology, 20189542Background: BRAF/MEK inhibition is standard of care in patients (pts) with a BRAF V600E/K mutated melanoma. Efficacy data for pts with less frequent BRAF mutations are limited so far.
Hassel, Jessica Cecile +18 more
openaire +1 more source
2010
Recent progress in the analysis of genetic alterations in melanoma has identified recurrent mutations that result in the activation of critical signaling pathways promoting growth and survival of tumors cells. Alterations in the RAS-RAF-MAP kinase and PI3-kinase signaling pathways are commonly altered in melanoma. Mutations in BRAF, NRAS, KIT, and GNAQ
Adil, Daud, Boris C, Bastian
openaire +2 more sources
Recent progress in the analysis of genetic alterations in melanoma has identified recurrent mutations that result in the activation of critical signaling pathways promoting growth and survival of tumors cells. Alterations in the RAS-RAF-MAP kinase and PI3-kinase signaling pathways are commonly altered in melanoma. Mutations in BRAF, NRAS, KIT, and GNAQ
Adil, Daud, Boris C, Bastian
openaire +2 more sources
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Targeted Oncology, 2018Malignant melanoma is the most aggressive and notorious skin cancer, and metastatic disease is associated with very poor long-term survival outcomes. Although metastatic melanoma patients with oncogenic mutations in the BRAF gene initially respond well to the treatment with specific BRAF inhibitors, most of them will eventually develop resistance to ...
Xiao, Liu +3 more
openaire +2 more sources